Biotech Company Announces Successful Completion of Cancer Treatment: 170,000 Dose Production

ImmunityBio's strategic investments and partnerships are set to play a pivotal role in shaping the future of cancer treatment.

ImmunityBio, Inc. (NASDAQ: IBRX) has announced the successful completion and qualification of the drug substance for ANKTIVA® (nogapendekin alfa inbakicept-pmln), paving the way for the production of 170,000 doses. This achievement underscores ImmunityBio's commitment to addressing critical needs in cancer treatment and highlights the company's strategi…